Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...

Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results , with sales up 16% year on year to ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...